Kim SH - Search Results

1

Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with N-Dimethylnitrosamine-Induced Liver Cirrhosis.

Bae SH, Choi HG, Park SY, Chang SY, Kim H, Kim SH. Bae SH, et al. Among authors: kim h, kim sh. Pharmaceutics. 2022 Dec 1;14(12):2684. doi: 10.3390/pharmaceutics14122684. Pharmaceutics. 2022. PMID: 36559177 Free PMC article.

2

Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats.

Yang SH, Choi HG, Lim SJ, Lee MG, Kim SH. Yang SH, et al. Among authors: kim sh. Oncol Rep. 2013 Mar;29(3):1215-23. doi: 10.3892/or.2012.2201. Epub 2012 Dec 19. Oncol Rep. 2013. PMID: 23254912

3

Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells.

Lim SJ, Choi HG, Jeon CK, Kim SH. Lim SJ, et al. Among authors: kim sh. Oncol Rep. 2015 Apr;33(4):2023-30. doi: 10.3892/or.2015.3775. Epub 2015 Feb 2. Oncol Rep. 2015. PMID: 25647149

4

Butyrate-mediated acquisition of chemoresistance by human colon cancer cells.

Kang HR, Choi HG, Jeon CK, Lim SJ, Kim SH. Kang HR, et al. Among authors: kim sh. Oncol Rep. 2016 Aug;36(2):1119-26. doi: 10.3892/or.2016.4838. Epub 2016 May 27. Oncol Rep. 2016. PMID: 27277338

5

Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells.

Bae SH, Park JH, Choi HG, Kim H, Kim SH. Bae SH, et al. Among authors: kim h, kim sh. Biomol Ther (Seoul). 2018 Sep 1;26(5):494-502. doi: 10.4062/biomolther.2018.042. Biomol Ther (Seoul). 2018. PMID: 30092625 Free PMC article.

6

ERdj5 in Innate Immune Cells Is a Crucial Factor for the Mucosal Adjuvanticity of Cholera Toxin.

Kim MS, Yi EJ, Kim YI, Kim SH, Jung YS, Kim SR, Iwawaki T, Ko HJ, Chang SY. Kim MS, et al. Among authors: kim sr, kim yi, kim sh. Front Immunol. 2019 Jun 4;10:1249. doi: 10.3389/fimmu.2019.01249. eCollection 2019. Front Immunol. 2019. PMID: 31275300 Free PMC article.

7

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism.

Lee JS, Kim SH. Lee JS, et al. Among authors: kim sh. Pharmaceutics. 2019 Jul 5;11(7):318. doi: 10.3390/pharmaceutics11070318. Pharmaceutics. 2019. PMID: 31284540 Free PMC article.

8

Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.

Gwak EH, Yoo HY, Kim SH. Gwak EH, et al. Among authors: kim sh. Biomol Ther (Seoul). 2020 Jul 1;28(4):361-369. doi: 10.4062/biomolther.2020.006. Biomol Ther (Seoul). 2020. PMID: 32209733 Free PMC article.

9

Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion.

Bae SH, Chang SY, Kim SH. Bae SH, et al. Among authors: kim sh. Pharmaceutics. 2020 Jul 30;12(8):714. doi: 10.3390/pharmaceutics12080714. Pharmaceutics. 2020. PMID: 32751547 Free PMC article.

10

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.

Lee JS, Kim HS, Jung YS, Choi HG, Kim SH. Lee JS, et al. Among authors: kim sh, kim hs. Pharmaceutics. 2021 May 18;13(5):740. doi: 10.3390/pharmaceutics13050740. Pharmaceutics. 2021. PMID: 34069798 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25,281 results

Search Page

Filters